Ads
related to: pfe stock performance
Search results
Results From The WOW.Com Content Network
PFE Revenue (TTM) data by YCharts Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of ...
Price Action: PFE stock is down 1.49% at $26.40 at the last check on Tuesday. Read Next: Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030
Pharmaceuticals giant Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings ...
Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE). When the COVID-19 pandemic began in 2020, Pfizer quickly ...
Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on ...
So far in 2022, however, Pfizer’s performance has been far less stellar. The vaccination wave peaked earlier this year, and revenue/earnings are expected to drop in 2023.InvestorPlace - Stock Mark
Pfizer's (NYSE:PFE) stock is up by a considerable 17% over the past month. Given that stock prices are usually aligned...
In the latest trading session, Pfizer (PFE) closed at $36.28, marking a -0.06% move from the previous day.